Straits Research released its highly anticipated report, “Global Direct-to-Consumer (DTC) Weight-Loss Medication Market Size & Outlook, 2026-2034”. According to the study, the global market size is valued at USD 8.64 billion in 2025 and is projected to expand to USD 35.61 billion by 2034, registering a compound annual growth rate (CAGR) of 17.08%.

Market Dynamics

The growth of the global direct-to-consumer (DTC) weight-loss medication market is strongly driven by the rising prevalence of obesity worldwide. According to the World Obesity Federation, over 1 billion people were living with obesity in 2024, a figure projected to reach 1.5 billion by 2035. This increasing obesity burden is fueling the adoption of DTC weight-loss medications, offering convenient access and enabling improved weight management. In addition, the growing integration of digital health and wellness solutions, such as mobile apps, telehealth platforms, and wearable devices, is creating significant market opportunities. These tools enhance patient adherence, allow for personalized treatment plans, and facilitate ongoing monitoring, making weight-loss interventions more effective and accessible. Moreover, rising health awareness among consumers and the proliferation of preventive healthcare initiatives are further encouraging the adoption of DTC weight management solutions, driving market expansion.

However, the high costs associated with prescription weight-loss medications, coupled with the potential for side effects, restrict widespread adoption in low and middle-income regions. Regulatory hurdles, including stringent approval processes for new formulations and safety monitoring requirements, also pose challenges for manufacturers and can slow product launches. On the other hand, innovations in formulation technologies, such as combination therapies and novel drug delivery systems, are enhancing the efficacy and tolerability of weight-loss medications.

Market Highlights

• Drug Class: The prescription drugs segment dominated the market in 2025 with a revenue share of 49.31%.
• Route of Administration: The injectable segment is estimated to grow at the fastest pace with a CAGR of 17.64%.
• Distribution Channel: The direct brand websites are expected to register the fastest CAGR of 18.59%. This growth is attributed to increasing adoption of telehealth platforms and direct-to-consumer prescription models.
• Regional Insights: North America dominated the global market, accounting for 38.67% share in 2025. This growth is attributed to the expansion of telemedicine and the rising prevalence of obesity.